{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:49:06Z","timestamp":1790401746886,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre"},{"DOI":"10.13039\/501100000380","name":"Guy's and St Thomas' Charity","doi-asserted-by":"crossref","award":["BRC-2011-10035"],"award-info":[{"award-number":["BRC-2011-10035"]}],"id":[{"id":"10.13039\/501100000380","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012176","name":"Maudsley Charity","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012176","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical Research Council","award":["MR\/J01219X\/1"],"award-info":[{"award-number":["MR\/J01219X\/1"]}]},{"name":"Medical Research Council","award":["MR\/L017105\/1"],"award-info":[{"award-number":["MR\/L017105\/1"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.schres.2016.04.010","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T18:00:13Z","timestamp":1460829613000},"page":"106-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Predictors of long-term (\u2265 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare"],"prefix":"10.1016","volume":"174","author":[{"given":"Giouliana","family":"Kadra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Downs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"MacCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.schres.2016.04.010_bb0005","first-page":"5","article-title":"Using antipsychotic agents in older patients","volume":"65","author":"Alexopoulos","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2016.04.010_bb0010","series-title":"Treatment of Patients With Schizophrenia","first-page":"1","author":"APA","year":"2004"},{"issue":"6","key":"10.1016\/j.schres.2016.04.010_bb0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/01.yic.0000224785.68040.43","article-title":"Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries","volume":"21","author":"Barbui","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2016.04.010_bb0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1192\/bjp.174.5.389","article-title":"Validation of the Health of the Nation Outcome Scales","volume":"174","author":"Bebbington","year":"1999","journal-title":"Br. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2016.04.010_bb0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004850-200511000-00004","article-title":"Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study","volume":"20","author":"Biancosino","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2016.04.010_bb0030","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11096-006-9063-1","article-title":"Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics\u2014a European study","volume":"29","author":"Broekema","year":"2007","journal-title":"Pharm. World Sci."},{"key":"10.1016\/j.schres.2016.04.010_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/appi.ajp.161.4.700","article-title":"Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits","volume":"161","author":"Centorrino","year":"2004","journal-title":"Am. J. Psychiatr."},{"issue":"7","key":"10.1016\/j.schres.2016.04.010_bb0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/hup.719","article-title":"Use of combinations of antipsychotics: McLean Hospital inpatients, 2002","volume":"20","author":"Centorrino","year":"2005","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"issue":"1","key":"10.1016\/j.schres.2016.04.010_bb0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a006928","article-title":"Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy","volume":"28","author":"Clark","year":"2002","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2016.04.010_bb0050","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.psc.2012.06.007","article-title":"Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice","volume":"35","author":"Correll","year":"2012","journal-title":"The Psychiatric Clinics of North America"},{"issue":"1\u20133","key":"10.1016\/j.schres.2016.04.010_bb0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.schres.2011.02.016","article-title":"Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior","volume":"131","author":"Correll","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.04.010_bb0060","series-title":"The English Indices of Deprivation 2010: Statistical Release","first-page":"1","author":"DCLG","year":"2011"},{"key":"10.1016\/j.schres.2016.04.010_bb0065","unstructured":"DoH (2007). Mental Health Act 2007. Retrieved January 30, 2015, from http:\/\/www.legislation.gov.uk\/ukpga\/2007\/12\/section\/32."},{"key":"10.1016\/j.schres.2016.04.010_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-5-26","article-title":"Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics","volume":"5","author":"Faries","year":"2005","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2016.04.010_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0447.2002.01331.x","article-title":"Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations","volume":"106","author":"Freudenreich","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2016.04.010_bb0080","article-title":"Homeless and mentally ill - a mental healthcare challenge for Europe","volume":"7","author":"Gaebel","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2016.04.010_bb0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.schres.2016.04.010_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.v65n1013","article-title":"Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998\u20132000","volume":"65","author":"Ganguly","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2016.04.010_bb0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/acps.12193","article-title":"Practitioner attitudes to clozapine initiation","volume":"130","author":"Gee","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.schres.2016.04.010_bb0100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jpsychores.2011.09.012","article-title":"Associations between symptoms and all-cause mortality in individuals with serious mental illness","volume":"72","author":"Hayes","year":"2012","journal-title":"J. Psychosom. Res."},{"issue":"6","key":"10.1016\/j.schres.2016.04.010_bb0105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation","volume":"201","author":"Howes","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.04.010_bb0110","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1192\/bjp.187.3.243","article-title":"Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription","volume":"187","author":"Ito","year":"2005","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2016.04.010_bb0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pds.783","article-title":"Antipsychotic medication coprescribing in a large state hospital system","volume":"12","author":"Jaffe","year":"2003","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"10.1016\/j.schres.2016.04.010_bb0120","first-page":"1","article-title":"Validation of polypharmacy process measures in inpatient schizophrenia care","volume":"30","author":"Janssen","year":"2005","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2016.04.010_bb0125","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1192\/bjp.188.2.122","article-title":"Schizophrenia, neuroleptic medication and mortality","volume":"188","author":"Joukama","year":"2006","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2016.04.010_bb0130","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12888-015-0557-z","article-title":"Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process","volume":"15","author":"Kadra","year":"2015","journal-title":"BMC Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2016.04.010_bb0135","doi-asserted-by":"crossref","DOI":"10.1176\/ps.2007.58.7.983","article-title":"Adding or switching antipsychotic medications in treatment","volume":"58","author":"Kreyenbuhl","year":"2007","journal-title":"Psychiatr. Serv."},{"issue":"4","key":"10.1016\/j.schres.2016.04.010_bb0140","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1176\/ps.2007.58.4.489","article-title":"Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns","volume":"58","author":"Kreyenbuhl","year":"2007","journal-title":"Psychiatr. Serv."},{"issue":"4","key":"10.1016\/j.schres.2016.04.010_bb0145","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0269881113477709","article-title":"Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness","volume":"27","author":"Lochmann van Bennekom","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2016.04.010_bb0150","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2045125314558054","article-title":"Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme","volume":"5","author":"Mace","year":"2015","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2016.04.010_bb0155","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-244X-11-118","article-title":"Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study","volume":"11","author":"Misawa","year":"2011","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2016.04.010_bb0160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clinthera.2007.01.002","article-title":"Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003","volume":"29","author":"Morrato","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.schres.2016.04.010_bb0165","series-title":"Schizophrenia. The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care","first-page":"1","author":"NICE","year":"2013"},{"issue":"11","key":"10.1016\/j.schres.2016.04.010_bb0170","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.euroneuro.2012.03.003","article-title":"Geographical and temporal variations in clozapine prescription for schizophrenia","volume":"22","author":"Nielsen","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2016.04.010_bb0175","series-title":"The English Indices of Deprivation 2007","author":"Noble","year":"2008"},{"issue":"2","key":"10.1016\/j.schres.2016.04.010_bb0180","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/2045125311407960","article-title":"Increased use of antipsychotic long-acting injections with community treatment orders","volume":"1","author":"Patel","year":"2011","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"10.1016\/j.schres.2016.04.010_bb0185","doi-asserted-by":"crossref","first-page":"e008721","DOI":"10.1136\/bmjopen-2015-008721","article-title":"Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) case register: current status and recent enhancement of an Electronic Mental Health Record derived data resource","volume":"6","author":"Perera","year":"2016","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.schres.2016.04.010_bb0190","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/YCO.0b013e32833f46c9","article-title":"Cardiovascular aspects of antipsychotics","volume":"23","author":"Raedler","year":"2010","journal-title":"Current Opinion in Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2016.04.010_bb0195","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/0269881113482530","article-title":"Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: a population-based, case-crossover study","volume":"27","author":"Shin","year":"2013","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"2","key":"10.1016\/j.schres.2016.04.010_bb0200","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2125.2004.02102.x","article-title":"Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia","volume":"58","author":"Sim","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2016.04.010_bb0205","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1192\/bjp.174.5.375","article-title":"Usefulness of the Health of the Nation Outcome Scale","volume":"174","author":"Stein","year":"1999","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2016.04.010_bb0210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-244X-9-51","article-title":"The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data","volume":"9","author":"Stewart","year":"2009","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2016.04.010_bb0215","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00127-012-0586-6","article-title":"Description of long-term polypharmacy among schizophrenia outpatients","volume":"48","author":"Suokas","year":"2012","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"issue":"5","key":"10.1016\/j.schres.2016.04.010_bb0220","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1192\/pb.26.5.170","article-title":"Co-prescribing of atypical and typical antipsychotics \u2013 prescribing sequence and documented outcome","volume":"26","author":"Taylor","year":"2002","journal-title":"Psychiatr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2016.04.010_bb0225","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1192\/bjp.173.4.325","article-title":"Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study","volume":"173","author":"Waddington","year":"1998","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2016.04.010_bb0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1192\/bjp.172.1.11","article-title":"Health of the Nation Outcome Scales (HoNOS). Research and development","volume":"172","author":"Wing","year":"1998","journal-title":"Br. J. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416301591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416301591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T18:34:43Z","timestamp":1668710083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996416301591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":46,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0920996416301591"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.04.010","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of long-term (\u22656months) antipsychotic polypharmacy prescribing in secondary mental healthcare","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}